Recent news headlines surrounding pharmaceutical giant Novartis highlight strong second-quarter performance with sales increasing to 14.4 billion dollars, beating analyst expectations despite generic competition for its former heart medication Entresto. Additionally, the company announced regulatory approvals and clinical data updates, including FDA approvals for Pluvicto in metastatic prostate cancer and Fabhalta for kidney function decline. Novartis also expanded its oncology and rare disease pipeline through strategic acquisitions like Myricx Bio while preparing for upcoming patent expirations on key blockbuster medications.